Pfizer, Inc. (NYSE:PFE) insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Pfizer, Inc. (NYSE PFE) opened at 35.36 on Friday. The firm has a market capitalization of $210.30 billion, a P/E ratio of 25.87 and a beta of 1.00. The stock’s 50 day moving average is $33.64 and its 200-day moving average is $33.53. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.84.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. Analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.

ILLEGAL ACTIVITY WARNING: “Sally Susman Sells 38,230 Shares of Pfizer, Inc. (PFE) Stock” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/16/sally-susman-sells-38230-shares-of-pfizer-inc-pfe-stock.html.

PFE has been the subject of a number of recent analyst reports. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Morgan Stanley restated a “neutral” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC restated a “neutral” rating and issued a $34.00 price objective on shares of Pfizer in a research report on Friday, June 16th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $37.72.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Davidson Kempner Capital Management LP acquired a new position in shares of Pfizer during the second quarter valued at about $5,039,000. W. E. Donoghue & Co. LLC acquired a new position in shares of Pfizer during the second quarter valued at about $16,402,000. Intl Fcstone Inc. grew its holdings in shares of Pfizer by 444.3% during the second quarter. Intl Fcstone Inc. now owns 56,081 shares of the biopharmaceutical company’s stock valued at $1,884,000 after buying an additional 45,777 shares during the last quarter. M Holdings Securities Inc. grew its holdings in shares of Pfizer by 41.5% during the second quarter. M Holdings Securities Inc. now owns 26,036 shares of the biopharmaceutical company’s stock valued at $875,000 after buying an additional 7,635 shares during the last quarter. Finally, Griffin Asset Management Inc. acquired a new position in shares of Pfizer during the second quarter valued at about $768,000. Hedge funds and other institutional investors own 69.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.